Study guide
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies
Key Takeaways Explain This Topic AI
Classical Hodgkin Lymphoma (cHL) is characterized by pathognomonic CD15+ / CD30+ Reed-Sternberg cells and staged using the Lugano classification with PET-CT response assessed via the 5-point Deauville criteria (Scores 1–3 indicate complete metabolic response; Scores 4–5 indicate residual active disease).
Frontline advanced cHL (Stage III/IV) treatment paradigms have shifted from ABVD to targeted and checkpoint-inhibitor chemoimmunotherapy: Nivolumab + AVD (N-AVD; SWOG S1826) demonstrates superior 2-year PFS (92% vs. 83%, HR 0.45) with reduced neuropathy and febrile neutropenia compared to Brentuximab Vedotin + AVD (A+AVD; ECHELON-1), while A+AVD remains an established standard requiring mandatory primary G-CSF prophylaxis.
Bleomycin pulmonary toxicity (BPT) risk increases with cumulative doses >=400 units, age >60, impaired renal clearance, G-CSF co-administration, and high FiO2 exposure; PET-adapted interim imaging (RATHL trial) permits safe bleomycin omission after 2 cycles for patients achieving Deauville 1–3 without compromising overall survival.
Relapsed or refractory cHL management prioritizes non-cross-resistant second-line chemoimmunotherapy (e.g., BV + Nivolumab, BV + Bendamustine, or ICE/DHAP) to achieve a complete metabolic response (PET-negative status) prior to consolidation with high-dose chemotherapy and Autologous Hematopoietic Cell Transplantation (auto-HCT).
Post-auto-HCT maintenance with brentuximab vedotin for up to 16 cycles significantly improves 5-year PFS (AETHERA trial, HR 0.52) in high-risk patients with primary refractory disease, early relapse within 12 months, or extranodal involvement at relapse.
Last updated: August 2026
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies
Hodgkin Lymphoma (HL) accounts for approximately 10% of all diagnosed lymphomas in the United States. It exhibits a distinctive bimodal age distribution, peaking in young adults aged 15–35 years and in older adults aged >=55 years. Modern risk-stratified, response-adapted chemoimmunotherapy regimens have established Hodgkin lymphoma as one of the most curable human malignancies, with 5-year overall survival rates exceeding 90% in early-stage disease and 80–85% in advanced-stage disease.
Board-certified oncology pharmacists (BCOP) play a central role in optimizing cure rates while mitigating long-term organ toxicities—specifically anthracycline cardiotoxicity, bleomycin-induced pulmonary fibrosis, secondary myeloid neoplasms, and fertility impairment—through rigorous biomarker interpretation, PET-adapted therapy adjustments, antimicrobial prophylaxis, and toxicity interception protocols.
1. Pathophysiology, Histopathology & Diagnostic Biomarkers
Hodgkin lymphoma is pathologically segregated into two major World Health Organization (WHO) categories based on morphology and immunophenotype:
Classical Hodgkin Lymphoma (cHL; ~95% of cases)
Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL; ~5% of cases) +---------------------------------------------------------------------------------------------------+
- | HODGKIN LYMPHOMA IMMUNOPHENOTYPIC MATRIX |
- | |
- | [CLASSICAL HODGKIN LYMPHOMA (cHL)] |
- | - Pathognomonic Cell: Hodgkin and Reed-Sternberg (HRS) cells (multinucleated "owl-eyed") |
- | - Characteristic Markers: **CD30+ (100%)**, **CD15+ (75-85%)**, PAX5+ (dim/weak) |
- | - Negative Markers: CD45- (LCA), CD20- (or variable/weak in <20%), CD3- |
- | - Microenvironment: Extensive inflammatory infiltrate (eosinophils, histiocytes, plasma cells) |
- | - Four Subtypes: |
- | 1. Nodular Sclerosis (NS; 70%): Lacunar cells, collagen bands, young females, mediastinal mass|
- | 2. Mixed Cellularity (MC; 20-25%): Abundant RS cells, strong EBV association, older males |
- | 3. Lymphocyte-Rich (LR; 5%): Best prognosis, background mature B-lymphocytes |
- | 4. Lymphocyte-Depleted (LD; <1%): Few lymphocytes, aggressive, elderly / HIV-positive |
- | |
- | [NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL)] |
- | - Pathognomonic Cell: Lymphocyte-predominant (LP) cells ("popcorn" cells) |
- | - Characteristic Markers: **CD20+**, **CD45+ (LCA)**, **BCL6+**, CD79a+ |
- | - Negative Markers: **CD30-**, **CD15-** |
- | - Clinical Behavior: Indolent, late relapses, managed similar to indolent B-cell NHL |
- +---------------------------------------------------------------------------------------------------+
- 2. Staging, Risk Stratification & PET Response Assessment
- Lugano Modification of Ann Arbor Staging System
Stage I: Involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ/site (IE).
Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single extralymphatic organ with regional lymph node involvement on the same side of the diaphragm (IIE).
Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which may include the spleen (IIIS).
Stage IV: Multifocal or diffuse involvement of one or more extralymphatic organs (e.g., bone marrow, liver, lung) with or without associated lymph node involvement.
Modifiers:
A / B Symptoms: "B" designation denotes unexplained fever (>38°C), drenching night sweats, or unexplained loss of >10% baseline body weight within the preceding 6 months. "A" denotes the absence of these constitutional symptoms.
Bulky Disease: Defined per Lugano as a single nodal mass >=10 cm in maximum dimension or a mediastinal mass exceeding one-third of the maximum internal transthoracic diameter on chest CT.
Early-Stage Risk Stratification (GHSG / EORTC Criteria)
Early-stage (Stage I–II) cHL is categorized into Early Favorable vs. Early Unfavorable based on clinical risk factors:
- Large mediastinal adenopathy (bulky mass >=10 cm or >0.33 thorax ratio)
- Age >=50 years
- Elevated erythrocyte sedimentation rate (ESR >=50 mm/h without B symptoms, or ESR >=30 mm/h with B symptoms)
- =3–4 involved nodal areas
- Presence of extranodal extension (E-lesions)
- Advanced-Stage International Prognostic Score (IPS / Hasenclever Score)
For advanced-stage (Stage III–IV) cHL, the IPS assigns 1 point for each of the following 7 baseline adverse factors (each point decreases 5-year freedom from progression by ~7–8%):
- Serum Albumin <4.0 g/dL
- Hemoglobin <10.5 g/dL
- Male gender
- Age >=45 years
- Stage IV disease
- Leukocytosis (WBC >=15,000/mcL)
Lymphopenia (ALC <600/mcL or <8% of total WBC) +---------------------------------------------------------------------------------------------------+
- | DEAUVILLE 5-POINT PET RESPONSE CRITERIA (Lugano) |
- | |
- | [Score 1]: No FDG uptake above background |
- | [Score 2]: FDG uptake <= mediastinal blood pool |
- | [Score 3]: FDG uptake > mediastinal blood pool but <= liver background |
- | ==> SCORES 1 to 3: Complete Metabolic Response (CMR / PET-Negative) |
- | |
- | [Score 4]: FDG uptake moderately higher than liver background at any site |
- | [Score 5]: FDG uptake markedly higher than liver background and/or new FDG-avid lesions |
- | [Score X]: New areas of uptake unlikely to be related to lymphoma (inflammatory/infection) |
- | ==> SCORES 4 to 5: Residual Active Disease / Treatment Failure (PET-Positive) |
- +---------------------------------------------------------------------------------------------------+
3. Frontline Systemic Treatment Regimens +---------------------------------------------------------------------------------------------------+
- | FRONTLINE ADVANCED CLASSICAL HODGKIN LYMPHOMA PARADIGM |
- | |
- | CLINICAL STAGE III or IV (or Stage I-II Unfavorable Bulky) |
- | | |
- | +-------------------------+-------------------------+ |
- | | | |
- | v v |
- | [N-AVD REGIMEN] (Preferred) [A+AVD REGIMEN] (Established) |
- | (SWOG S1826: Herrera et al. NEJM 2024) (ECHELON-1: Connors NEJM 2018 / Ansell 2022) |
- | - Nivolumab: 240 mg IV D1, D15 - Brentuximab Vedotin: 1.2 mg/kg IV D1, D15 |
- | - Doxorubicin: 25 mg/m2 IV D1, D15 - Doxorubicin: 25 mg/m2 IV D1, D15 |
- | - Vinblastine: 6 mg/m2 IV D1, D15 - Vinblastine: 6 mg/m2 IV D1, D15 |
- | - Dacarbazine: 375 mg/m2 IV D1, D15 - Dacarbazine: 375 mg/m2 IV D1, D15 |
- | - Q28D x 6 Cycles (12 Doses) - Q28D x 6 Cycles (12 Doses) |
- | - 2-Year PFS: 92% vs 83% (HR 0.45, p<0.001) - 6-Year OS: 93.9% vs 89.4% (HR 0.59) |
- | - Neuropathy: Low (G3: 1%) - Peripheral Neuropathy: 67% (G3: 11%) |
- | - G-CSF: As clinically indicated - PRIMARY G-CSF PROPHYLAXIS: MANDATORY! |
- | - Toxicity: irAEs (Hypothyroidism 13%) - Bleomycin Omitted: ZERO Pulmonary Toxicity |
- +---------------------------------------------------------------------------------------------------+
- Detailed Analysis of Frontline Regimens
Regimen Drug Components & Dosing Schedule Cycle Length & Duration Key Clinical Trial Evidence Primary Toxicities & Pharmacist Interventions
N-AVD Nivolumab 240 mg IV (or 3 mg/kg in pediatrics); Doxorubicin 25 mg/m2 IV; Vinblastine 6 mg/m2 IV (max 10 mg); Dacarbazine 375 mg/m2 IV; All administered on Days 1 and 15 28 days x 6 cycles (12 total treatments) SWOG S1826 (n=970; Herrera et al. NEJM 2024). Randomized vs. BV-AVD in patients >=12 years old. 2-year PFS: 92% vs. 83% (HR 0.45, p < 0.001) . Preferred Category 1 frontline regimen. Dramatically lower neuropathy and infection rates than BV-AVD. Monitor for immune-related adverse events (irAEs: hypothyroidism 13%, rash, transaminitis, colitis). G-CSF is used as-needed, not mandatory.
A+AVD Brentuximab vedotin 1.2 mg/kg IV (max 120 mg); Doxorubicin 25 mg/m2 IV; Vinblastine 6 mg/m2 IV (max 10 mg); Dacarbazine 375 mg/m2 IV; All administered on Days 1 and 15 28 days x 6 cycles (12 total treatments) ECHELON-1 (n=1,334; Connors et al. NEJM 2018; 6-year OS: Ansell et al. NEJM 2022). 6-year OS: 93.9% vs. 89.4% (HR 0.59, p = 0.009) . Primary G-CSF prophylaxis is mandatory starting at Cycle 1 Day 1 (without G-CSF, febrile neutropenia rate was 21%). High peripheral sensory neuropathy (67%; Grade 3 in 11%); dose-modify BV to 0.9 mg/kg for Grade 2, hold for Grade >=3. Zero bleomycin lung toxicity.
ABVD Doxorubicin 25 mg/m2 IV; Bleomycin 10 units/m2 IV (max 10 units); Vinblastine 6 mg/m2 IV (max 10 mg); Dacarbazine 375 mg/m2 IV; All administered on Days 1 and 15 28 days x 2–6 cycles depending on stage Historical standard. RATHL trial (Johnson et al. NEJM 2016): Bleomycin safely omitted after cycle 2 in PET2-negative (DS 1–3) patients without compromising 3-yr PFS (84.4% vs 85.7%). Bleomycin pulmonary toxicity (BPT): cough, dyspnea, basilar crackles, drop in DLCO. Avoid G-CSF co-administration with bleomycin (exacerbates alveolar lung injury). Extravasation: Doxorubicin (vesicant -> dexrazoxane/cold); Vinblastine (vesicant -> hyaluronidase/warm).
Escalated BEACOPP Bleomycin 10 mg/m2 D8; Etoposide 200 mg/m2 D1–3; Doxorubicin 35 mg/m2 D1; Cyclophosphamide 1250 mg/m2 D1; Vincristine 1.4 mg/m2 D8 (max 2 mg); Procarbazine 100 mg/m2 PO D1–7; Prednisone 40 mg/m2 PO D1–14 21 days x 4–6 cycles + routine G-CSF support GHSG HD18 Trial (Borstmann et al. Lancet 2017). High cure rates in high-risk advanced cHL; PET4-negative allows de-escalation to 4 total cycles. High acute and late toxicities: severe neutropenic sepsis, secondary myelodysplasia / AML (1.5–3.0%), permanent infertility (>90% azoospermia in males, premature ovarian failure in females). Rarely used in the US given modern N-AVD / A+AVD options.
4. Bleomycin Pulmonary Toxicity (BPT) & Pharmacist Interception Protocols
Bleomycin is an antineoplastic glycopeptide antibiotic that binds Fe(II) and oxygen to generate reactive oxygen species (ROS), causing DNA single- and double-strand breaks. Because lung tissue and skin are deficient in bleomycin hydrolase (the cytoplasmic deactivating aminopeptidase enzyme), the lung is uniquely vulnerable to oxidative endothelial injury, organizing alveolitis, and irreversible pulmonary fibrosis.
Clinical Risk Factors for BPT
Cumulative lifetime dose >=400 units (incidence rises sharply above 400 units; absolute ceiling typically 400 units)
- Age >60 years
- Renal insufficiency (creatinine clearance <50–60 mL/min ; 60–70% of bleomycin is renally excreted intact)
High fraction of inspired oxygen ( FiO2 >30–40% during general anesthesia or supplemental O2 triggers fatal ARDS)
Prior mediastinal radiation therapy
Concomitant administration of granulocyte colony-stimulating factors ( G-CSF / filgrastim / pegfilgrastim ), which amplifies alveolar neutrophil influx and superoxide generation +---------------------------------------------------------------------------------------------------+
- | BLEOMYCIN PULMONARY TOXICITY (BPT) MONITORING & MANAGEMENT |
- | |
- | BASELINE ASSESSMENT: |
- | - Pulmonary Function Tests (PFTs) with DLCO (Diffusing Capacity of the Lung for Carbon Monoxide)|
- | - Baseline 2D-Echocardiogram (LVEF for doxorubicin) and baseline renal function (CrCl) |
- | |
- | INTERIM PET-ADAPTED PROTOCOL (RATHL Protocol): |
- | - Perform PET-CT after Cycle 2 (PET2) |
- | - If Deauville Score 1 - 3 (PET-negative): **OMIT BLEOMYCIN from Cycles 3 to 6 (AVD alone)** |
- | - If Deauville Score 4 - 5 (PET-positive): Escalate therapy to escalated BEACOPP or Salvage |
- | |
- | CLINICAL SYMPTOM SURVEILLANCE & ACTIONS: |
- | - Symptoms: Nonproductive dry cough, exertional dyspnea, pleuritic substernal pain, fever |
- | - Physical Exam: Bilateral inspiratory dry "velcro" basilar crackles (crepitations) |
- | - PFT Trigger: Drop in **DLCO >=15-20% from baseline** OR new interstitial infiltrates on CT |
- | - IMMEDIATE ACTION: **PERMANENTLY DISCONTINUE BLEOMYCIN!** (Never rechallenge!) |
- | - Pharmacotherapy: High-dose systemic corticosteroids (Prednisone 0.75-1 mg/kg/day or IV |
- | Methylprednisolone 1-2 mg/kg/day) tapered over 4 to 8 weeks |
- +---------------------------------------------------------------------------------------------------+
- 5. Relapsed & Refractory Classical Hodgkin Lymphoma Management
Approximately 10–15% of patients with early-stage cHL and 20–30% with advanced-stage cHL experience primary refractory disease (failure to achieve CMR or progression within 3 months of frontline therapy) or disease relapse.
Therapeutic Algorithm for Transplant-Eligible Relapse
The standard curative-intent strategy for chemosensitive relapsed/refractory cHL in transplant-eligible patients is Second-Line Salvage Therapy to achieve Complete Metabolic Response (PET-negative) followed by High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation (auto-HCT) . +---------------------------------------------------------------------------------------------------+
- | RELAPSED / REFRACTORY cHL SALVAGE & CONSOLIDATION ALGORITHM |
- | |
- | BIOPSY-PROVEN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA |
- | | |
- | v |
- | [SECOND-LINE SYSTEMIC SALVAGE CHEMOIMMUNOTHERAPY] |
- | - Option 1 (Preferred Novel): **Brentuximab Vedotin + Nivolumab** (Moskowitz 2021; CMR ~67-79%) |
- | - Option 2 (Immune Backbone): **Pembrolizumab + GVD** (Gemcitabine, Vinorelbine, Liposomal Dox)|
- | - Option 3 (Cytotoxic Salvage): **ICE** (Ifosfamide, Carboplatin, Etoposide + Mesna) OR |
- | **DHAP** (Dexamethasone, High-Dose Cytarabine, Cisplatin) OR |
- | **IGEV** (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone) |
- | | |
- | v |
- | [INTERIM RESTAGING PET-CT SCAN] |
- | | |
- | +-------------------------+-------------------------+ |
- | | | |
- | v v |
- | [PET-NEGATIVE: Deauville 1-3] [PET-POSITIVE: Deauville 4-5] |
- | | | |
- | v v |
- | [HIGH-DOSE CHEMOTHERAPY (BEAM) + AUTO-HCT] [NON-CROSS-RESISTANT THIRD-LINE SALVAGE] |
- | - Carmustine (BCNU) 300 mg/m2 D-6 - Switch to PD-1 inhibitor (Pembrolizumab) |
- | - Etoposide 100-200 mg/m2 BID D-5 to D-2 or Brentuximab Vedotin if not yet exposed |
- | - Cytarabine 100-200 mg/m2 BID D-5 to D-2 - Goal: Attain CMR prior to Auto-HCT |
- | - Melphalan 140 mg/m2 D-1 | |
- | - Stem Cell Infusion Day 0 v |
- | | [Consolidate with Auto-HCT once PET-negative]|
- | v |
- | [POST-TRANSPLANT MAINTENANCE EVALUATION] |
- | - Assess AETHERA Risk Criteria: |
- | * Primary refractory disease (no complete remission to frontline therapy) |
- | * Early relapse (<12 months from completion of frontline therapy) |
- | * Extranodal disease involvement at the time of relapse pre-salvage |
- | - If High-Risk (>=1 factor present): **BRENTUXIMAB VEDOTIN MAINTENANCE** |
- | * Dose: 1.8 mg/kg IV every 3 weeks starting Day +30 to +45 post-HCT |
- | * Duration: Up to 16 cycles (~1 year) |
- | * AETHERA Trial: 5-year PFS 59% vs. 41% (HR 0.52, p < 0.001) |
- +---------------------------------------------------------------------------------------------------+
- Post-Transplant & Third-Line Systemic Targeted Agents
Therapeutic Agent Mechanism & Regimen Landmark Clinical Trial Data Toxicity Profile & Clinical Monitoring
Pembrolizumab Anti-PD-1 monoclonal antibody; Dose: 200 mg IV Q3W or 400 mg IV Q6W KEYNOTE-204 (n=304; Kuruvilla et al. Lancet Oncol 2021). Randomized vs. Brentuximab vedotin in post-auto-HCT or transplant-ineligible relapse. Median PFS: 13.2 vs. 8.3 months (HR 0.65, p = 0.0027) . Immune-related adverse events: pneumonitis (11%), colitis, endocrinopathies (hypothyroidism/hyperthyroidism 19%), hepatitis. High response in 9p24.1 amplified cHL.
Nivolumab Anti-PD-1 monoclonal antibody; Dose: 240 mg IV Q2W or 480 mg IV Q4W CheckMate 205 (Ansell et al. Lancet Oncol 2016). Evaluated in cohorts post-auto-HCT and post-BV. Overall response rate: 69–73% , median duration of response >16 months. Similar irAE profile to pembrolizumab. Note: Checkpoint inhibitors administered prior to allogeneic HCT increase risks of hyperacute/severe GVHD and graft failure.
Brentuximab Vedotin Anti-CD30 antibody-drug conjugate linked via protease-cleavable linker to monomethyl auristatin E (MMAE); Dose: 1.8 mg/kg IV Q3W Pivotal Phase 2 (Younes et al. JCO 2012) and AETHERA Maintenance Trial (Moskowitz et al. Lancet 2015). Post-HCT maintenance 5-year PFS 59% vs 41% (HR 0.52) . Peripheral sensory neuropathy (56–67%) , neutropenia, anemia, rare progressive multifocal leukoencephalopathy (PML). Strong CYP3A4 inhibitors increase MMAE AUC.